FDA PMA FDA Class 3 Approved 🇺🇸 United States

System, Hyperthermia, Rf/Microwave (Benign Prostatic Hyperplasia),Thermotherapy

PMA: P970008 · Supplement: S026 · Decision Jun 16, 2005
Classifications
1
FEI Numbers
10
Registration Numbers
10

Basic Information

Device Name
System, Hyperthermia, Rf/Microwave (Benign Prostatic Hyperplasia),Thermotherapy
Trade Name
UROLOGIX TARGIS SYSTEM FOR THE TREATMENT OF BPH
PMA Number
P970008
Supplement Number
S026
Device Class
FDA Class 3
Product Code
MEQ
Generic Name
System, hyperthermia, rf/microwave (benign prostatic hyperplasia),thermotherapy
Medical Specialty
Unknown
Advisory Committee
Gastroenterology, Urology
Decision
Approved
Decision Code
APPR
Decision Date
June 16, 2005
Date Received
February 25, 2005
Supplement Type
Normal 180 Day Track
Supplement Reason
Change Design/Components/Specifications/Material
Expedited Review
N

Advisory Committee Statement

APPROVAL FOR A LONGER VERSION OF THE COOLED THERMOCATH MICROWAVE DELIVERY CATHETER. THE LONGER ANTENNA IS 37 MM COMPARED TO THE 28 MM ANTENNA IN THE CURRENTLY APPROVED COOLED THERMOCATH CATHETER. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME COOLED THERMOCATH 4.5+ AND IS INDICATED FOR MEN WITH PROSTATIC URETHRAL LENGTHS OF 4.5 CM OR GREATER.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
MEQ System, Hyperthermia, Rf/Microwave (Benign Prostatic Hyperplasia),Thermotherapy